Management of Follicular Lymphoma and the Role of Novel Agents Need to be Defined

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Professor of Clinical Hematology, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2017, vol. 7, issue 2, 30-33

Abstract: FL is a very heterogenous disease as would be expected by the diversity of mutation seen at genomic level and in the microenvironment from patient to patient. With the exception of limited-stage disease, FL is generally considered an incurable malignancy with a median life expectancy of approximately ten years. In patients for whom standard therapies fail, several novel agents are promising.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555710.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555710.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:7:y:2017:i:2:p:30-33

DOI: 10.19080/CTOIJ.2017.07.555710

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().